Communication and education about the available health coverage options was important in keeping consumers informed about enrollment, which Jennifer Sullivan, director of the Best Practices Institute at Enroll America, said was key in engaging consumers.
Communication and education about the available health coverage options was important in keeping consumers informed about enrollment, which Jennifer Sullivan, director of the Best Practices Institute at Enroll America, said was key in engaging consumers.
Transcript (slightly modified)
How has Enroll America’s strategy of engaging consumers evolved over the first 3 years of open enrollment?
Early on, I think the most important thing really was to focus on the fact that coverage was coming. Coverage was coming, financial help is here. We found that in order to connect as many people as possible to this information, big enrollment events were really important. We often saw lines wrapping out of buildings.
As the effort has evolved, we’ve been able to work strategically with community partners, with members of the local media, to make sure that consumers are getting the information they need and the in-person help they need from trusted members of their community.
We’ve certainly seen a lot of improvements in the consumer experience, both in terms of the opportunities to enroll, the ways consumers interact with the website and really empowering them with the information that they need to make smart decisions about the plan. There’s just ever increasing transparency around what plans are available, and allowing consumers to make personalized decisions about what’s best for them.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More